Sarepta (SRPT) sinks 20% as surprise FDA AdComm for SRP-9001 adds risk
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Sarepta Therapeutics (SRPT) PT Lowered to $160 at Needham & Company
March 17, 2023 6:22 AM EDTNeedham & Company analyst Gil Blum lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $160.00 (from $200.00) while maintaining a Buy rating.... More
Sarepta Therapeutics (SRPT) PT Lowered to $139 at Credit Suisse
March 17, 2023 6:03 AM EDTCredit Suisse analyst Judah C. Frommer lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $139.00 (from $144.00) while maintaining a Neutral rating.... More
Sarepta Therapeutics (SRPT) 30-day option implied volatility at 44
March 17, 2023 3:08 AM EDTSarepta Therapeutics (NASDAQ: SRPT) 30-day option implied volatility is at 44; compared to its 52-week range of 39 to 74 into disclosing FDA AdCom meeting to be held for SRP-9001.
... MoreAfter-hours movers: First Republic resumes free-fall despite lifeline, FedEx surges on raised guidance
March 16, 2023 5:47 PM EDTAfter-Hours Stock Movers:
First Republic Bank (NYSE: FRC) 25% LOWER; falls despite getting a $30 billion lifeline from the nation's largest banks today. Shares rose 10% intra-day.
Sarepta Therapeutics (SRPT) announced AdCom to be held for SRP-9001
March 16, 2023 5:44 PM EDTSarepta Therapeutics, Inc. (NASDAQ: SRPT) announced that at its late cycle meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA), the U.S. Food and Drug Administrations Office of Therapeutics (OTP) has determined that an advisory committee meeting will be held for SRP-9001 in advance of the May 29, 2023 regulatory action date. SRP-9001 is Sareptas investigational gene therapy for the treatment of Duchenne muscular dystrophy.
FDAs... More
